Frequency, risk factors, and outcome of acute kidney injury following bone marrow transplantation at Dr Shariati Hospital in Tehran

  • F. S
  • I. N
  • M.S. H
 et al. 
  • 2


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Introduction. Bone marrow transplantation (BMT) is a major modality for malignant and hematologic disorders. This procedure is associated with a high morbidity and mortality such as acute kidney injury (AKI). Many factors, such as therapeutic agents, irradiation, and graft versus host disease (GVHD) can cause AKI. Bone marrow transplantation conditioning therapy in Iran is based on drugs such as busulfan and cyclophosphamide and without irradiation therapy. The aim of this study was to evaluate the frequency, risk factors, and mortality of AKI among patients who underwent BMT. Materials and Methods. Acute kidney injury was defined as doubling serum creatinine from baseline at any time during the first 180 days posttransplant. The risk of AKI in relation to nontotal-body- irradiation-based conditioning regimen, type of graft (allograft and autograft), comorbidities, GVHD, drug toxicity, and veno-occlusive disease were examined in 375 patients with BMT. Results. One hundred and forty-two patients (37.6%) developed AKI at a median of 18 days after transplant. A higher frequency of AKI was observed in patients who received cyclosporine A (40%), patients with allograft BMT (42.1%), and those who developed gastrointestinal GVHD (47.3%) .The remainder AKI cases were associated with amphotericin B, veno-occlusive disease, and hemolytic-uremic syndrome. Conclusions. The frequency of AKI in our patients with BMT remained high. Cyclosporine A and amphotericin B and the presence of GVHD and veno-occlusive disease increased the risk of AKI within the first 180 days after BMT.

Author-supplied keywords

  • *bone marrow transplantation
  • *kidney injury/co [Complication]
  • *kidney injury/ep [Epidemiology]
  • *kidney injury/si [Side Effect]
  • Iran
  • adolescent
  • adult
  • amikacin/ae [Adverse Drug Reaction]
  • amikacin/cb [Drug Combination]
  • amphotericin B
  • amphotericin/ae [Adverse Drug Reaction]
  • antiinfective agent/dt [Drug Therapy]
  • article
  • busulfan/cb [Drug Combination]
  • cephalosporin/cb [Drug Combination]
  • child
  • comorbidity
  • cyclophosphamide/cb [Drug Combination]
  • cyclosporin A/dt [Drug Therapy]
  • cyclosporin/ae [Adverse Drug Reaction]
  • female
  • fever/dt [Drug Therapy]
  • fever/pc [Prevention]
  • graft versus host reaction/co [Complication]
  • graft versus host reaction/dt [Drug Therapy]
  • graft versus host reaction/pc [Prevention]
  • hemolytic uremic syndrome
  • human
  • major clinical study
  • male
  • methotrexate/ae [Adverse Drug Reaction]
  • methotrexate/dt [Drug Therapy]
  • morbidity
  • mortality
  • neutropenia/dt [Drug Therapy]
  • neutropenia/pc [Prevention]
  • postoperative period
  • prednisone/dt [Drug Therapy]
  • preschool child
  • prophylaxis
  • risk factor
  • school child
  • vancomycin/cb [Drug Combination]
  • vein occlusion

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Saddadi F.

  • Najafi I.

  • Hakemi M.S.

  • Falaknazi K.

  • Attari F.

  • Bahar B.

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free